Selimoglu Mukadder Ayse, Ertekin Vildan, Doneray Hakan, Yildirim Mustafa
Faculty of Medicine, Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University, Malatya.
J Clin Gastroenterol. 2008 Feb;42(2):194-8. doi: 10.1097/MCG.0b013e318032388d.
Osteoporosis accompanying chronic liver disease is well known; however, the exact prevalence is unknown. No data on bone mineral density (BMD) of children with Wilson disease (WD) have been published so far. In this study, we aimed to investigate the prevalence of osteoporosis in childhood WD and to observe the probable positive effects of penicillamine and zinc therapy on osteoporosis.
Thirty-one children with newly diagnosed WD and sex and age-matched 16 healthy children were included. Mean age was 9.0+/-3.2 years (2 to 16 y). Bone mineral content (BMC) and BMD were measured on admission and in 13 cases they were reassessed after 1 year of treatment with penicillamine and zinc.
Mean BMD, BMC, and Z scores of the patients were significantly lower than those of healthy children: 0.52+/-0.09 versus 0.72+/-0.09 (P=0.001), 19.27+/-13.01 versus 29.67+/-14.23 (P=0.009), and -2.33+/-1.28 versus -0.12+/-0.31 (P=0.001), respectively. The prevalence of osteopenia and osteoporosis in children with WD was found as 22.6% and 67.7%, respectively. BMD and BMC levels were higher in children with neurologic involvement. The severity of the disease had no effect on the mentioned parameters. One year under treatment with penicillamine and zinc did not significantly alter the mentioned parameters.
In this first study investigating the prevalence of osteoporosis in children with WD, we found an extremely high prevalence. Because of nonbeneficial effect of routine treatment of WD on osteoporosis, we emphasize the necessity of screening of bone mineralization and additional therapeutic approach for those children.
骨质疏松症与慢性肝病并存已广为人知;然而,确切患病率尚不清楚。目前尚无关于肝豆状核变性(WD)患儿骨密度(BMD)的数据发表。在本研究中,我们旨在调查儿童WD中骨质疏松症的患病率,并观察青霉胺和锌疗法对骨质疏松症可能产生的积极影响。
纳入31例新诊断的WD患儿以及16例年龄和性别匹配的健康儿童。平均年龄为9.0±3.2岁(2至16岁)。入院时测量骨矿物质含量(BMC)和BMD,其中13例在接受青霉胺和锌治疗1年后重新评估。
患者的平均BMD、BMC和Z评分显著低于健康儿童:分别为0.52±0.09对0.72±0.09(P=0.001),19.27±13.01对29.67±14.23(P=0.009),以及-2.33±1.28对-0.12±0.31(P=0.001)。WD患儿中骨量减少和骨质疏松症的患病率分别为22.6%和67.7%。有神经受累的儿童BMD和BMC水平较高。疾病严重程度对上述参数无影响。接受青霉胺和锌治疗1年并未显著改变上述参数。
在这项首次调查WD患儿骨质疏松症患病率的研究中,我们发现患病率极高。由于WD的常规治疗对骨质疏松症无有益作用,我们强调对这些儿童进行骨矿化筛查和额外治疗方法的必要性。